恒瑞医药：公司以多元化战略为支柱，解决包括老年或慢病患者等人群的临床未满足需求

Core Viewpoint - Heng Rui Medicine emphasizes its commitment to a technology innovation strategy, expanding its product pipeline to address unmet clinical needs in chronic disease management while continuing to deepen its focus on oncology [1] Group 1: R&D Strategy - The company is broadening its research and development efforts beyond oncology to include metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [1] - Several innovative products have already been approved for market, targeting conditions such as type 2 diabetes, atopic dermatitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, and hypercholesterolemia [1] Group 2: Product Pipeline - The company has a diverse pipeline with dozens of new drugs currently in clinical development [1]